quantisnow
FeedTopReportsPricing
⌘K
Live feed
11:58:00·554d
PRRelease
Kintara Therapeutics Inc. logo

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

KTRA· Kintara Therapeutics Inc.
Health Care
Original source

Companies

  • KTRA
    Kintara Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jan 20UpdateHC Wainwright & Co.$3.00
  • Sep 30UpdateAegis Capital$5.00
  • Sep 28UpdateHC Wainwright & Co.$6.00

Related

  • PR31d
    Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
  • PR288d
    Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development
  • INSIDER548d
    SEC Form 4 filed by Chief Scientific Officer Yamashita Dennis
  • INSIDER548d
    New insider Patel Vijay claimed ownership of 7,999,557 shares (SEC Form 3)
  • INSIDER548d
    SEC Form 4 filed by Director Ng George K
  • INSIDER548d
    New insider Ng George K claimed no ownership of stock in the company (SEC Form 3)
  • INSIDER548d
    SEC Form 4 filed by Director List Alan
  • INSIDER548d
    New insider List Alan claimed no ownership of stock in the company (SEC Form 3)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022